o2h discovery is pleased to announce a productive multi FTE chemistry collaboration with ImmuNext to support their cutting-edge drug discovery program focused on developing new Antibody Drug Conjugates.
ImmuNext is developing immune-based therapies to treat patients with immune-related disorders, including inflammatory disease, autoimmune disorders, cancer, transplantation rejection, and infectious disease. They target critical immunomodulatory molecules that either promote or suppress immune responses to restore immune homeostasis and cure disease.
o2h discovery is delighted to provide synthetic chemistry support to help ImmuNext create new linker-payloads to deliver their groundbreaking ADCs to patients.
Jay Rothstein, CSO of ImmuNext said: “o2h has helped us innovate novel payload-linker combinations for our INX200 program.Their expertise in medicinal chemistry along with their commitment to quality products and timely delivery was critical for our program’s success”
Hemal Soni, Head of Chemistry of o2h discovery, said: “It has been a pleasure to support ImmuNext on their chemistry projects. The ImmuNext team has been an absolute pleasure to work with, and we are happy that by working together, we were able to provide an effective and productive outcome for some complex targets and help ImmuNext achieve their essential project milestones.”
About o2h discovery:
Founded in 2005, o2h discovery is a Contract Research Organisation which has an integrated drug discovery platform operating from our state-of-the-art research centre in India and The Mill SciTech Park, Cambridge, UK. We have the in-house capability to execute hit-lead-optimization programs leading into patent and IND filing from our state-of-the-art biotechnology incubator with expertise in discovery chemistry, biology, pharmacology, and the ongoing project management of pre-clinical development.
o2h discovery has developed and launched its proprietary application Chemistry in the Cloud™ (CITC), the world’s first app to revolutionize the project management of external drug discovery programs. The app enables the communication between various scientific stakeholders essential to successful project advancement – leading to faster decision making.
The DNA of o2h discovery is centered around the nurturing of its people, values, and culture. It reflects in the way we work with each other, as well as our collaborators and partners.
ImmuNext is a preclinical drug discovery company that develops novel immunotherapies for the treatment of autoimmune disease and cancer. ImmuNext has partnered immunotherapies with Janssen, Roche, Sanofi, Eli Lilly and Curis. Assets are currently in Phase 1 and Phase 2 trials.
For more information, please visit- www.immunext.com